Literature DB >> 25085841

Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.

Volker Vallon1, Neil G Docherty2.   

Abstract

The tubular hypothesis of glomerular filtration and nephropathy in diabetes is a pathophysiological concept that assigns a critical role to the tubular system, including proximal tubular hyper-reabsorption and growth, which is relevant for early glomerular hyperfiltration and later chronic kidney disease. Here we focus on how harnessing the bioactivity of hormones released from the gut may ameliorate the early effects of diabetes on the kidney in part by attenuating proximal tubular hyper-reabsorption and growth. The endogenous tone of the glucagon-like peptide 1 (GLP-1)/GLP-1 receptor (GLP-1R) system and its pharmacological activation are nephroprotective in diabetes independent of changes in blood glucose. This is associated with suppression of increases in kidney weight and glomerular hyperfiltration, which may reflect, at least in part, its inhibitory effects on tubular hyper-reabsorption and growth. Inhibition of dipeptidyl peptidase 4 (DPP-4) is also nephroprotective independent of changes in blood glucose and involves GLP-1/GLP-1R-dependent and -independent mechanisms. The GLP-1R agonist exendin-4 induces natriuresis via activation of the GLP-1R. In contrast, DPP4 inhibition increases circulating GLP-1, but drives a GLP-1R-independent natriuretic response, implying a role for other DPP-4 substrates. The extent to which the intrarenal DPP-4/GLP-1 receptor system contributes to all these changes remains to be established, as does the direct impact of the system on renal inflammation.
© 2014 The Authors. Experimental Physiology © 2014 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25085841      PMCID: PMC4162767          DOI: 10.1113/expphysiol.2014.078766

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  29 in total

Review 1.  Regulation of renal function by the gastrointestinal tract: potential role of gut-derived peptides and hormones.

Authors:  A R Michell; E S Debnam; R J Unwin
Journal:  Annu Rev Physiol       Date:  2008       Impact factor: 19.318

2.  Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.

Authors:  P Schlatter; C Beglinger; J Drewe; H Gutmann
Journal:  Regul Pept       Date:  2007-01-10

3.  Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans.

Authors:  Jean-Pierre Gutzwiller; Petr Hruz; Andreas R Huber; Christian Hamel; Carlos Zehnder; Juergen Drewe; Heike Gutmann; Zeno Stanga; Daniel Vogel; Christoph Beglinger
Journal:  Digestion       Date:  2006       Impact factor: 3.216

4.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.

Authors:  Minsuk Kim; Mathew J Platt; Tadao Shibasaki; Susan E Quaggin; Peter H Backx; Susumu Seino; Jeremy A Simpson; Daniel J Drucker
Journal:  Nat Med       Date:  2013-03-31       Impact factor: 53.440

5.  Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.

Authors:  S Nakashima; T Matsui; M Takeuchi; S-I Yamagishi
Journal:  Horm Metab Res       Date:  2014-04-07       Impact factor: 2.936

Review 6.  Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.

Authors:  Leonard Ralph Forte
Journal:  Pharmacol Ther       Date:  2004-11       Impact factor: 12.310

7.  Dipeptidyl peptidase IV, a kidney brush-border serine peptidase.

Authors:  A J Kenny; A G Booth; S G George; J Ingram; D Kershaw; E J Wood; A R Young
Journal:  Biochem J       Date:  1976-07-01       Impact factor: 3.857

8.  GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

Authors:  Brian D Green; Katharine V Hand; Janette E Dougan; Bronagh M McDonnell; Roslyn S Cassidy; David J Grieve
Journal:  Arch Biochem Biophys       Date:  2008-08-07       Impact factor: 4.013

9.  SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

Authors:  Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-13

10.  DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells.

Authors:  Wei-Jie Wang; Chen-Hung Chang; Mao-Feng Sun; Sheng-Feng Hsu; Ching-Sung Weng
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

View more
  11 in total

Review 1.  Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Alice Sabatino; Giuseppe Regolisti; Carmela Cosola; Loreto Gesualdo; Enrico Fiaccadori
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

Review 2.  Cardiovascular, renal and overall health outcomes after bariatric surgery.

Authors:  Ji C Tham; Carel W le Roux; Neil G Docherty
Journal:  Curr Cardiol Rep       Date:  2015-05       Impact factor: 2.931

3.  The normal increase in insulin after a meal may be required to prevent postprandial renal sodium and volume losses.

Authors:  Debra L Irsik; Bonnie L Blazer-Yost; Alexander Staruschenko; Michael W Brands
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-03-22       Impact factor: 3.619

Review 4.  Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Authors:  Bassant Orabi; Rasha Kaddoura; Amr S Omar; Cornelia Carr; Abdulaziz Alkhulaifi
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

5.  Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.

Authors:  Carmen Wolke; Alexander Teumer; Karlhans Endlich; Nicole Endlich; Rainer Rettig; Sylvia Stracke; Beate Fiene; Simone Aymanns; Stephan B Felix; Anke Hannemann; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-30

6.  Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.

Authors:  Hiroki Esaki; Tomoya Tachi; Chitoshi Goto; Ikuto Sugita; Yuta Kanematsu; Aki Yoshida; Kosuke Saito; Yoshihiro Noguchi; Yuki Ohno; Satoshi Aoyama; Masahiro Yasuda; Takashi Mizui; Masumi Yamamura; Hitomi Teramachi
Journal:  Front Pharmacol       Date:  2017-11-15       Impact factor: 5.810

Review 7.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

Review 8.  Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM).

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Ecaterina Neculae; Claudia Florida Costea; Manuela Ciocoiu; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Minela Aida Maranduca; Cristina Mihaela Lacatusu; Mariana Floria; Ionela Lacramioara Serban
Journal:  Nutrients       Date:  2020-12-02       Impact factor: 5.717

Review 9.  Renoprotective Effects of DPP-4 Inhibitors.

Authors:  Daiji Kawanami; Yuichi Takashi; Hiroyuki Takahashi; Ryoko Motonaga; Makito Tanabe
Journal:  Antioxidants (Basel)       Date:  2021-02-05

Review 10.  Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review.

Authors:  Rodrigo Daza-Arnedo; Jorge-Eduardo Rico-Fontalvo; Nehomar Pájaro-Galvis; Víctor Leal-Martínez; Emilio Abuabara-Franco; María Raad-Sarabia; Juan Montejo-Hernández; María Cardona-Blanco; José Cabrales-Juan; Isabella Uparella-Gulfo; Luis Salgado Montiel
Journal:  Kidney Med       Date:  2021-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.